Abstract
Ovarian cancer is the sixth most common cancer worldwide and the seventh most common cause of deaths from cancer in women. Recent annual worldwide figures reflect 204,000 new cases of ovarian cancer and 125,000 deaths. Treatment of advanced ovarian cancer involves a combination of surgery and chemotherapy, both of which may impact a woman's physical, social, and emotional well-being. A woman's quality of life (QOL) is affected by disease site, and treatment-specific and patient-specific factors, but other common QOL issues include changes in physical functioning owing to side effects of treatment, psychological distress caused by fear and anxiety of recurrence, sexual dysfunction associated with anatomic and physiologic changes of treatment, and for younger women, loss of childbearing potential. As new diagnostic and treatment strategies for gynecologic malignancies are developed, research efforts should include QOL consequences. Further studies are needed to develop strategies for identifying women at risk for serious QOL disruption so that effective interventions to assist these women can be designed.
Key Points
-
Most women with epithelial ovarian cancer are diagnosed with stage III and IV disease and require cytoreductive surgery followed by platinum-based chemotherapy
-
Women diagnosed with and treated for ovarian cancer may encounter significant disruption in their day-to-day lives owing to their multiple social roles and the clinical course of the disease
-
For some women, cytoreductive surgery for ovarian cancer may cause premature menopause, sexual dysfunction, or infertility, all of which have major implications on quality of life
-
Primary postoperative chemotherapy consists of 6-8 cycles of platinum-based and taxane-based chemotherapy; however, several treatment regimens are used in the setting of recurrent disease, and include platinum and/or taxane agents, and second-line agents such as liposomal doxorubicin, topotecan, and gemcitabine
-
The majority of women will undergo multiple regimens of chemotherapy throughout their lives and may experience treatment-related side effects including nausea and vomiting, peripheral neuropathy, alopecia, neutropenia, anemia, and fatigue
-
Events associated with progressive disease highlight issues of palliative care, such as surgical versus medical management of malignant bowel obstruction, repeated paracentesis for ascites, and/or multiple thoracentesis for pleural effusions
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Parkin DM et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108
Ozols R et al. (2005) Epithelial ovarian cancer. In Principles and Practice of Gynecologic Oncology, 895–987 (Eds Hoskins W et al.) Philadelphia: Lippincott Williams & Wilkins
Boyd J (2003) Hereditary ovarian cancer: what we know. Gynecol Oncol 88 (Suppl): S8–S10
Goff BA et al. (2000) Ovarian carcinoma diagnosis. Cancer 89: 2068–2075
Goff BA et al. (2004) Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291: 2705–2712
Olson SH et al. (2001) Symptoms of ovarian cancer. Obstet Gynecol 98: 212–217
Stirling D et al. (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics system. J Clin Oncol 23: 5588–5596
Menon U et al. (2005) Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23: 7919–7926
Munoz KA et al. (1997) Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 15: 3408–3415
Armstrong DK et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43
FIGO Staging Committee (1986) International Federation of Gynecology and Obstetrics Staging Announcement. Gynecol Oncol 25: 383–385
Bristow RE et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–1259
Bookman M (2006) GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract #5002]. J Clin Oncol
Taylor KL et al. (2004) Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst 96: 1083–1094
Cella DF and Bonomi AE (1995) Measuring quality of life: 1995 update. Oncology (Williston Park) 9: 47–60
Ahlberg K et al. (2005) The experience of fatigue, other symptoms and global quality of life during radiotherapy for uterine cancer. Int J Nurs Stud 42: 377–386
Bergmark K et al. (2002) Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand 81: 443–450
Chan YM et al. (2003) Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 88: 9–16
Ell K et al. (2005) Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J Clin Oncol 23: 3052–3060
Fallowfield LJ et al. (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24: 910–917
Frumovitz M et al. (2005) Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 23: 7428–7436
Herbst RS et al.; American Society of Clinical Oncology (2006) Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 24: 190–205
Janda M et al. (2004) Vulvar cancer patients' quality of life: a qualitative assessment. Int J Gynecol Cancer 14: 875–881
Le T et al. (2003) Quality-of-life issues in patients with ovarian cancer and their caregivers: a review. Obstet Gynecol Surv 58: 749–758
Gillette-Cloven N et al. (2001) Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg 193: 626–632
Payne SA (1992) A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 35: 1505–1509
Ratliff CR et al. (1996) Sexual adjustment of patients undergoing gracilis myocutaneous flap vaginal reconstruction in conjunction with pelvic exenteration. Cancer 78: 2229–2235
Roos EJ et al. (2004) Quality of life after pelvic exenteration. Gynecol Oncol 93: 610–614
Taphoorn MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumour Group; EORTC Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group (2005) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6: 937–944
Zhu L et al. (2005) Quality-of-life analysis in the management of endometrial cancer. Am J Obstet Gynecol 192: 1388–1390
Gordon AN et al. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of peglyated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3321–3322
Coenen M et al. (2000) Gemcitabine in platinum-paclitaxel resistant ovarian carcinoma [abstract]. Proc Am Soc Clin Oncol 19: a603
Freidlander M et al. (1998) A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 9: 1343–1345
Lund B et al. (1994) Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530–1533
Rose PG et al. (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16: 405–410
Aaronson NK et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376
Cella DF et al. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11: 570–579
Cull A et al. (2001) Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37: 47–53
Greimel E et al. (2003) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39: 1402–1408
Basen-Engquist K et al. (2001) Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 19: 1809–1817
Stiggelbout AM and de Haes JC (2001) Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol 19: 220–230
Calhoun EA et al. (2004) A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol 93: 164–169
Sun CC et al. (2002) Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 87: 118–128
Sun CC et al. (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13: 219–227
Graziottin A and Basson R (2004) Sexual dysfunction in women with premature menopause. Menopause 11: 766–777
Rossouw JE et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333
Loprinzi CL et al. (1998) Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 16: 2377–2381
Barton D et al. (2002) Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 29: 33–40
Kimmick GG et al. (2006) Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 12: 114–122
Bodurka D et al. (2005) Ovarian cancer: quality of life issues. Boca Raton: National Ovarian Cancer Coalition
Wenzel LB et al. (2002) Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology 11: 142–153
Carmack Taylor CL et al. (2004) Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol 22: 881–889
Penson RT et al. (2004) Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol 94: 427–435
Stead ML et al. (2001) Communication about sexual problems and sexual concerns in ovarian cancer: qualitative study. BMJ 323: 836–837
Bodurka DCSC et al. (2005) Helping cancer patients with quality of life treatment decisions (audio CD). ACOG update 31: October 2005
Stewart DE et al. (2001) ”What doesn't kill you makes you stronger”: an ovarian cancer survivor survey. Gynecol Oncol 83: 537–542
Tabano M et al. (2002) Symptoms affecting quality of life in women with gynecologic cancer. Semin Oncol Nurs 18: 223–230
Wenzel L et al. (2005) Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr (34): 94–98
Friedman LC and Kramer RM (2005) Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr (34): 83–86
Robson M et al. (2003) Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 89: 281–287
Chi DS et al. (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103: 559–564
Eisenkop SM and Spirtos NM (2001) Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol 82: 435–441
Pothuri B et al. (2003) Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol 89: 306–313
Pothuri B et al. (2005) Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 96: 330–334
Kim Y and Morrow GR (2003) Changes in family relationships affect the development of chemotherapy-related nausea symptoms. Support Care Cancer 11: 171–177
Lindley CM et al. (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1: 331–340
O'Brien BJ et al. (1993) Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ 149: 296–302
Doherty KM (1993) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3: 113–119
Hesketh PJ (2000) Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18: 163–173
Oo TH and Hesketh PJ (2005) Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol 2: 196–201
Kris MG et al. (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24: 2932–2947
Edwards SJ (2003) Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer. Semin Oncol Nurs 19: 19–39
Camp-Sorrell D (2000) Chemotherapy: toxicity management. In Cancer Nursing Principles and Practice, 444–486 (Eds Yarbro C et al.) Sudbury: Jones and Bartlett
Sweeney CW (2002) Understanding peripheral neuropathy in patients with cancer: background and patient assessment. Clin J Oncol Nurs 6: 163–166
Ocean AJ and Bahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12: 619–625
Visovsky C (2003) Chemotherapy-induced peripheral neuropathy. Cancer Invest 21: 439–451
Boling W et al. (2003) Health-related quality of life in gynecological oncology: instruments and psychometric properties. Int J Gynecol Cancer 13: 5–14
Carelle N et al. (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95: 155–163
National Comprehensive Cancer Network (2006) Cancer- and treatment-related anemia. Cancer Practice Guidelines in Oncology, Version 1 [http://www.nccn.org] (accessed 28 November 2006)
Ludwig H and Strasser K (2001) Symptomatology of anemia. Semin Oncol 28: 7–14
Groopman JE and Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616–1634
Holzner B et al. (2003) Fatigue in ovarian carcinoma patients: a neglected issue? Cancer 97: 1564–1572
Elit L et al. (2001) Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer 1: 149–156
Fry A et al. (2001) Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 10: 231–241
Norton TR et al. (2004) Prevalence and predictors of psychological distress among women with ovarian cancer. J Clin Oncol 22: 919–926
Ferrell B et al. (2003) Psychological well being and quality of life in ovarian cancer survivors. Cancer 98: 1061–1071
Howell D et al. (2003) Impact of ovarian cancer perceived by women. Cancer Nurs 26: 1–9
Hamilton AB (1999) Psychological aspects of ovarian cancer. Cancer Invest 17: 335–341
Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519–2529
Ozols RF (2005) Treatment goals in ovarian cancer. Int J Gynecol Cancer 15 (Suppl 1): S3–S11
Daugherty C et al. (1995) Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13: 1062–1072
Doyle C et al. (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19: 1266–1274
Horng S et al. (2002) Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 347: 2134–2140
von Gruenigen VE and Daly BJ (2005) Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 97: 638–644
Baile WF et al. (1999) Discussing disease progression and end-of-life decisions. Oncology (Williston Park) 13: 1021–1031; discussion 1031–1036, 1038
Chu C and Rubin SC (2004) Management of intestinal obstruction in the terminal patient and management of ascites. In Gynecologic Cancer: Controversies in Management, 727–741 (Eds Gershenson DM et al.) Philadelphia: Elsevier Ltd
Whitworth MK et al. (2004) Doctor, does this mean I'm going to starve to death? J Clin Oncol 22: 199–201
Buckman R and Baile W (2004) Death and dying. In Gynecologic Cancer: Controversies in Management, 743–752 (Eds Gershenson DM et al.) Philadelphia: Elsevier Ltd
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Sun, C., Ramirez, P. & Bodurka, D. Quality of life for patients with epithelial ovarian cancer. Nat Rev Clin Oncol 4, 18–29 (2007). https://doi.org/10.1038/ncponc0693
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0693
This article is cited by
-
Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India
Supportive Care in Cancer (2022)
-
Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer
Supportive Care in Cancer (2017)
-
Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy
International Journal of Clinical Oncology (2017)
-
Issues of ovarian cancer survivors in the USA: a literature review
Supportive Care in Cancer (2013)
-
Ovarian cancer surgery: health and coping during the perioperative period
Supportive Care in Cancer (2013)